INT184390

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 3.29
Pain Relevance 3.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (Arhgap4) nucleus (Arhgap4) cytoplasm (Arhgap4)
Anatomy Link Frequency
capsule 1
B cell 1
CII 1
Arhgap4 (Mus musculus)
Pain Link Frequency Relevance Heat
Morphine 25 100.00 Very High Very High Very High
Arthritis 146 99.44 Very High Very High Very High
Potency 10 98.20 Very High Very High Very High
Eae 30 97.84 Very High Very High Very High
spinal inflammation 1 96.68 Very High Very High Very High
Glutamate receptor 10 96.52 Very High Very High Very High
Antinociceptive 150 95.44 Very High Very High Very High
Inflammation 113 95.04 Very High Very High Very High
Glutamate 78 94.68 High High
qutenza 75 94.28 High High
Disease Link Frequency Relevance Heat
Arthritis 160 99.44 Very High Very High Very High
Nociception 55 98.08 Very High Very High Very High
Inflammatory Pain 6 97.84 Very High Very High Very High
Seronegative Spondarthritis 2 97.64 Very High Very High Very High
Infection 49 96.84 Very High Very High Very High
Ankylosing Spondylitis 1 96.68 Very High Very High Very High
Disease 125 95.40 Very High Very High Very High
INFLAMMATION 120 95.04 Very High Very High Very High
Targeted Disruption 32 88.00 High High
Stress 30 86.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
During the development of CIA, increasing levels of anti-CII antibodies bind to the collagen of the articular cartilage, activate the complement system and initiate tissue damage; this indicates that there is T-B cell cooperation and activation in vivo [47,48].
CII Binding (bind) of in B cell associated with arthritis
1) Confidence 0.36 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656239 Disease Relevance 1.01 Pain Relevance 0.49
We believe that the CII epitope density on the intact cartilage surface is too low for classical-route complement fixation by bound anti-CII IgG antibodies.
CII Binding (bound) of in CII
2) Confidence 0.35 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175046 Disease Relevance 0.40 Pain Relevance 0.20
Results from immunohistochemistry suggest that Lys c-1 binds to the oocyst stage, perhaps forming part of the oocyst capsule wall.
Lys c-1 Binding (binds) of in capsule
3) Confidence 0.35 Published 2006 Journal Journal of Insect Science Section Body Doc Link PMC2990333 Disease Relevance 0.32 Pain Relevance 0
Compounds C1 and C2 were evaluated in the hot-plate thermal nociception model by p.o. route.
C1 Binding (Compounds) of associated with nociception
4) Confidence 0.28 Published 2010 Journal BMC Pharmacol Section Body Doc Link PMC2817697 Disease Relevance 0.24 Pain Relevance 0.43
This assay was used during the initial studies with compounds C1 and C2 in order to establish differences in potency using different routes of administration.
C1 Binding (compounds) of associated with potency
5) Confidence 0.28 Published 2010 Journal BMC Pharmacol Section Body Doc Link PMC2817697 Disease Relevance 0.18 Pain Relevance 0.81
Different groups of animals (n = 8) were treated p.o. with compounds C1 and C2 (300 mg.kg-1), morphine hydrochloride (20 mg.kg-1), or vehicle, or i.p. with compounds C1 and C2 (10, 30, 100, 300 mg.kg-1) or vehicle.
C1 Binding (compounds) of associated with morphine
6) Confidence 0.28 Published 2010 Journal BMC Pharmacol Section Body Doc Link PMC2817697 Disease Relevance 0.16 Pain Relevance 0.42
Different groups of animals (n = 8) were treated i.p. with compounds C1 and C2 (10, 30, 100 and 300 mg.kg-1) (dose- related to determine ED50).
C1 Binding (compounds) of
7) Confidence 0.28 Published 2010 Journal BMC Pharmacol Section Body Doc Link PMC2817697 Disease Relevance 0.22 Pain Relevance 0.49
Different groups of animals (n = 8) were treated p.o. with compounds C1 and C2 (300 mg.kg-1), morphine hydrochloride (20 mg.kg-1), or vehicle, or i.p. with compounds C1 and C2 (10, 30, 100, 300 mg.kg-1) or vehicle.
C1 Binding (compounds) of associated with morphine
8) Confidence 0.28 Published 2010 Journal BMC Pharmacol Section Body Doc Link PMC2817697 Disease Relevance 0.15 Pain Relevance 0.40
Its effects include binding to and subsequent inactivation of C1, inhibition of MAC assembly, and blockage of the formation of C3 convertase (Baker et al 1975; Hughes-Jones and Gardner 1978; Almeda et al 1983; Weiler 1983).
C1 Binding (binding) of
9) Confidence 0.03 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727911 Disease Relevance 0 Pain Relevance 0
Antibody interference assays have shown that complex C1 is composed of Sp1 whereas complexes C2 and C3 consist mainly of Sp3 [9,15].
C1 Binding (complex) of
10) Confidence 0.02 Published 2008 Journal Cell Signal Section Body Doc Link PMC2586094 Disease Relevance 0 Pain Relevance 0
Another subunit of C1, C1r, cleaves and activates the third subunit of C1, C1s.
C1 Binding (subunit) of
11) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727911 Disease Relevance 0.33 Pain Relevance 0
Its effects include binding to and subsequent inactivation of C1, inhibition of MAC assembly, and blockage of the formation of C3 convertase (Baker et al 1975; Hughes-Jones and Gardner 1978; Almeda et al 1983; Weiler 1983).
C1 Binding (binding) of
12) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727911 Disease Relevance 0 Pain Relevance 0
In the classical pathway, one of the main complement regulatory proteins is C1 inhibitor (C1-INH), which binds to the C1r:C1s complex and causes it to dissociate from C1q, thus preventing activation of the complement system.
C1 Binding (binds) of
13) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727911 Disease Relevance 0.30 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox